- In southern New England, we have the only multidisciplinary consortium with a dedicated team of medical oncologists, radiation oncologists and neurosurgeons who focus specifically on the management of brain metastases and providing comprehensive brain cancer care.
- We lead the way nationally in the use of newer agents such as immunotherapy and targeted therapies specifically for brain metastases.
- Patients have access to a full range of treatment options, from medical therapy to cutting-edge laser brain surgery.
- Yale Medicine uses state-of-the-art equipment and world-renowned experts who work together to offer patients the best possible multidisciplinary care.
When a metastatic brain tumor is diagnosed, it means that cancer cells from another organ have spread to the brain.
Metastatic tumors are the most common type of brain cancer today —about 10 times more common than cancers that originate within the brain (such as gliomas or meningiomas). The prevalence of brain metastases is increasing because cancer treatment has advanced considerably; instead of living just months after cancer diagnosis, many people live years with the disease, or their cancers go into remission. An estimated 200,000 new cases of brain metastases are now diagnosed in the U.S. every year.
Just a decade ago, finding a brain metastasis meant a person's average life expectancy was no more than six months, making aggressive treatment not worthwhile. That's no longer the case. With longer survival rates, neurosurgery is increasingly used to treat brain metastases.
Our dedicated team of oncologists and neurosurgeons focus specifically on the management of brain metastases. At Yale Medicine our world-renowned experts use state-of-the-art equipment to provide patients the best possible multidisciplinary care.